• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Allogeneic hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: a report of three cases and literature review].[异基因造血干细胞移植治疗施瓦茨曼-戴蒙德综合征:三例报告及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):689-693. doi: 10.3760/cma.j.cn121090-20240107-00009.
2
Outcomes of allogeneic hematopoietic stem cell transplantation in Shwachman-Diamond syndrome: a systematic review and meta-analysis.
Cytotherapy. 2025 Apr;27(4):465-474. doi: 10.1016/j.jcyt.2024.12.004. Epub 2024 Dec 17.
3
First experience of hematopoietic stem cell transplantation treatment of Shwachman-Diamond syndrome using unaffected HLA-matched sibling donor produced through preimplantation HLA typing.应用植入前 HLA 配型选择非亲缘 HLA 相合供者行造血干细胞移植治疗 Shwachman-Diamond 综合征:初步经验
Bone Marrow Transplant. 2017 Sep;52(9):1249-1252. doi: 10.1038/bmt.2017.46. Epub 2017 Mar 27.
4
Successful allogeneic hematopoietic stem cell transplantation (HSCT) for Shwachman-Diamond syndrome.成功进行异基因造血干细胞移植治疗施瓦赫曼-戴蒙德综合征。
Bone Marrow Transplant. 2002 Jan;29(1):75-9. doi: 10.1038/sj.bmt.1703321.
5
Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances.Shwachman-Diamond 综合征中骨髓恶性肿瘤的易感性:生物学见解和临床进展。
Blood. 2023 Mar 30;141(13):1513-1523. doi: 10.1182/blood.2022017739.
6
[Haploidentical stem cell transplantation for acute myeloid leukemia associated with adult-onset Shwachman-Diamond syndrome].单倍体相合干细胞移植治疗成人起病的施-戴二氏综合征相关急性髓系白血病
Rinsho Ketsueki. 2022;63(2):94-98. doi: 10.11406/rinketsu.63.94.
7
Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study.施瓦茨曼-戴蒙德综合征合并骨髓增生异常综合征或急性髓系白血病患者的临床特征及预后:一项多中心、回顾性队列研究
Lancet Haematol. 2020 Mar;7(3):e238-e246. doi: 10.1016/S2352-3026(19)30206-6. Epub 2019 Dec 23.
8
Diagnosis, Treatment, and Molecular Pathology of Shwachman-Diamond Syndrome.施瓦赫曼-戴蒙德综合征的诊断、治疗及分子病理学
Hematol Oncol Clin North Am. 2018 Aug;32(4):687-700. doi: 10.1016/j.hoc.2018.04.006. Epub 2018 Jun 5.
9
Clinical features, epidemiology, and treatment of Shwachman-Diamond syndrome: a systematic review.Shwachman-Diamond 综合征的临床特征、流行病学和治疗:系统评价。
BMC Pediatr. 2023 Oct 6;23(1):503. doi: 10.1186/s12887-023-04324-3.
10
Shwachman-Diamond Syndrome: Molecular Mechanisms and Current Perspectives.Shwachman-Diamond 综合征:分子机制与研究现状。
Mol Diagn Ther. 2019 Apr;23(2):281-290. doi: 10.1007/s40291-018-0368-2.

本文引用的文献

1
Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis.同种异体造血细胞移植后移植物功能不良的多能间充质基质细胞治疗:一项多中心前瞻性分析。
Front Immunol. 2023 Feb 1;14:1106464. doi: 10.3389/fimmu.2023.1106464. eCollection 2023.
2
Analysis of the Efficacy and Safety of Avatrombopag Combined With MSCs for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation.分析阿伐曲泊帕联合间充质干细胞治疗异基因造血干细胞移植后血小板减少症的疗效和安全性。
Front Immunol. 2022 May 27;13:910893. doi: 10.3389/fimmu.2022.910893. eCollection 2022.
3
Sars-CoV-2 Virus Infection May Interfere CD34+ Hematopoietic Stem Cells and Megakaryocyte-Erythroid Progenitors Differentiation Contributing to Platelet Defection towards Insurgence of Thrombocytopenia and Thrombophilia.严重急性呼吸综合征冠状病毒2(Sars-CoV-2)感染可能干扰CD34+造血干细胞和巨核细胞-红系祖细胞的分化,导致血小板缺陷,进而引发血小板减少症和血栓形成倾向。
Microorganisms. 2021 Jul 30;9(8):1632. doi: 10.3390/microorganisms9081632.
4
Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.不同的遗传途径定义了 Shwachman-Diamond 综合征中恶性前与代偿性克隆性造血。
Nat Commun. 2021 Feb 26;12(1):1334. doi: 10.1038/s41467-021-21588-4.
5
Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia.依洛尤单抗治疗可促进血小板恢复,减少移植后血小板减少症患者的血小板输注。
Ann Hematol. 2020 Nov;99(11):2679-2687. doi: 10.1007/s00277-020-04106-2. Epub 2020 Jun 9.
6
[Clinical features and gene mutations of children with Shwachman-Diamond syndrome and malignant myeloid transformation].[施瓦赫曼-戴蒙德综合征患儿的临床特征及基因突变与恶性髓系转化]
Zhongguo Dang Dai Er Ke Za Zhi. 2020 May;22(5):460-465. doi: 10.7499/j.issn.1008-8830.2001133.
7
Hematopoietic Stem Cell Transplantation for Shwachman-Diamond Syndrome.施瓦赫曼-戴蒙德综合征的造血干细胞移植
Biol Blood Marrow Transplant. 2020 Aug;26(8):1446-1451. doi: 10.1016/j.bbmt.2020.04.029. Epub 2020 May 16.
8
Successful Umbilical Cord Blood Transplantation With Reduced-intensity Conditioning for Acute Myeloid Leukemia in a Child With Shwachman-Diamond Syndrome.舒-戴二氏综合征患儿接受减低强度预处理的脐带血移植治疗急性髓系白血病获得成功。
J Pediatr Hematol Oncol. 2021 Apr 1;43(3):e414-e418. doi: 10.1097/MPH.0000000000001773.
9
Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation.巴利昔单抗治疗亲缘单倍体造血干细胞移植后儿童患者激素耐药性急性移植物抗宿主病。
Biol Blood Marrow Transplant. 2020 Feb;26(2):351-357. doi: 10.1016/j.bbmt.2019.10.031. Epub 2019 Nov 5.
10
Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植后原发性移植物功能不良的发生率、危险因素和结局。
Biol Blood Marrow Transplant. 2019 Sep;25(9):1898-1907. doi: 10.1016/j.bbmt.2019.05.036. Epub 2019 Jun 6.

[异基因造血干细胞移植治疗施瓦茨曼-戴蒙德综合征:三例报告及文献复习]

[Allogeneic hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: a report of three cases and literature review].

作者信息

Feng A H, Shi J M, Fu H R, Yu J, Zheng W Y, Zhu Y Y, Huang H, Zhao Y M

机构信息

Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China Department of Hematology, Affiliated Hospital of Shandong Second Medical University, Weifang 261035, China.

Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):689-693. doi: 10.3760/cma.j.cn121090-20240107-00009.

DOI:10.3760/cma.j.cn121090-20240107-00009
PMID:39231775
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11388119/
Abstract

This study reports on three patients with Shwachman-Diamond syndrome (SDS) who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at the First Affiliated Hospital of Zhejiang University School of Medicine. Based on relevant literature, the clinical manifestations and genetic mutation characteristics of SDS were summarized, and the efficacy and timing of allo HSCT for such patients were explored. Three SDS patients were all male, with transplant ages of 32, 33, and 32 years old, respectively. All three patients were diagnosed in childhood. Case 1 presented with anemia as the initial clinical manifestation, which gradually progressed to a decrease in whole blood cells; Case 2 and 3 both present with a decrease in whole blood cells as the initial clinical manifestation. Case 1 and 3 have intellectual disabilities, while case 3 presents with pancreatic steatosis and chronic pancreatitis. All three patients have short stature. Three patients all detected heterozygous mutations in the SBDS: c.258+2T>C splice site. The family members of the three patients have no clinical manifestations of SDS. All three patients were treated with a reduced dose pre-treatment regimen (Fludarabine+Busulfan+Me-CCNU+Rabbit Anti-human Thymocyte Globulin). Case 1 and case 2 underwent haploid hematopoietic stem cell transplantation, while case 3 underwent unrelated donor hematopoietic stem cell transplantation. Case 1 was diagnosed with myelodysplastic syndrome transforming into acute myeloid leukemia before transplantation, but experienced early recurrence and death after transplantation; Case 2 is secondary implantation failure, dependent on platelet transfusion; Case 3 was removed from medication maintenance treatment after transplantation, and blood routine monitoring was normal.

摘要

本研究报告了3例在浙江大学医学院附属第一医院接受异基因造血干细胞移植(allo-HSCT)的施瓦赫曼-戴蒙德综合征(SDS)患者。基于相关文献,总结了SDS的临床表现和基因突变特征,并探讨了此类患者allo-HSCT的疗效及时机。3例SDS患者均为男性,移植年龄分别为32岁、33岁和32岁。3例患者均在儿童期确诊。病例1以贫血为初始临床表现,逐渐进展为全血细胞减少;病例2和3均以全血细胞减少为初始临床表现。病例1和3有智力障碍,病例3有胰腺脂肪变性和慢性胰腺炎。3例患者均身材矮小。3例患者均检测到SBDS基因杂合突变:c.258+2T>C剪接位点。3例患者的家庭成员均无SDS临床表现。3例患者均采用减低剂量预处理方案(氟达拉滨+白消安+司莫司汀+兔抗人胸腺细胞球蛋白)治疗。病例1和病例2接受单倍体造血干细胞移植,病例3接受非血缘供者造血干细胞移植。病例1在移植前诊断为骨髓增生异常综合征转化为急性髓系白血病,移植后早期复发死亡;病例2为继发性植入失败,依赖血小板输注;病例3移植后停用药物维持治疗,血常规监测正常。